BVF as of March 31, 2015
Portfolio Holdings for BVF
BVF holds 30 positions in its portfolio as reported in the March 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Array BioPharma | 14.5 | $69M | 9.4M | 7.37 | |
| Chemocentryx | 13.1 | $63M | 8.3M | 7.55 | |
| Ironwood Pharmaceuticals (IRWD) | 7.3 | $35M | 2.2M | 16.00 | |
| Forward Pharma A/s | 7.0 | $33M | 1.2M | 28.32 | |
| Oncomed Pharmaceuticals | 6.9 | $33M | 1.3M | 25.78 | |
| Exelixis Inc cnv | 5.0 | $24M | 31M | 0.77 | |
| Oncothyreon | 4.9 | $23M | 14M | 1.63 | |
| Ligand Pharmaceuticals In (LGND) | 4.3 | $21M | 267k | 77.11 | |
| Concert Pharmaceuticals I equity | 4.2 | $20M | 1.3M | 15.14 | |
| Targacept | 4.1 | $20M | 6.7M | 2.97 | |
| Vitae Pharmaceuticals | 3.9 | $19M | 1.6M | 11.71 | |
| Qlt | 3.4 | $16M | 4.1M | 3.91 | |
| Cytokinetics (CYTK) | 3.0 | $14M | 2.1M | 6.78 | |
| Loxo Oncology | 2.9 | $14M | 1.1M | 12.45 | |
| ArQule | 2.9 | $14M | 6.2M | 2.24 | |
| Exelixis (EXEL) | 2.7 | $13M | 5.0M | 2.57 | |
| Five Prime Therapeutics | 2.4 | $12M | 503k | 22.85 | |
| GTx | 1.6 | $7.6M | 11M | 0.68 | |
| Xenon Pharmaceuticals (XENE) | 1.4 | $6.6M | 391k | 16.86 | |
| Sunesis Pharmaceuticals | 1.0 | $4.6M | 1.9M | 2.45 | |
| Mast Therapeutics | 0.7 | $3.5M | 7.2M | 0.48 | |
| Biolinerx Ltd-spons | 0.7 | $3.2M | 1.5M | 2.11 | |
| OncoGenex Pharmaceuticals | 0.6 | $2.9M | 1.4M | 2.15 | |
| Regado Biosciences | 0.5 | $2.3M | 1.9M | 1.22 | |
| Achaogen | 0.3 | $1.3M | 137k | 9.76 | |
| Mei Pharma | 0.2 | $1.1M | 600k | 1.79 | |
| Aptose Biosciences | 0.2 | $907k | 167k | 5.44 | |
| Biota Pharmaceuticals | 0.2 | $807k | 351k | 2.30 | |
| Sophiris Bio | 0.1 | $615k | 1.1M | 0.58 | |
| Kalobios Pharmaceuticals | 0.1 | $569k | 1.2M | 0.49 |
